Abstracts tagged "clinical research and osteoarthritis"

Abstract Number: 1365 • 2018 ACR/ARHP Annual Meeting
A Phase IIa Study of Anti-GM-CSF Antibody GSK3196165 in Subjects with Inflammatory Hand Osteoarthritis
Georg Schett¹, Chris Bainbridge², Mario Berkowitz³, Katherine Davy⁴, Sofia Fernandes⁵, Eduard Griep⁶, Stephen Harrison⁷, Mark Layton⁸, Nonna Anna Nowak⁹, Jatin Patel⁵, Juergen Rech¹, Sarah Watts⁴ and Paul-Peter Tak⁵, ¹Department of Internal Medicine 3, University of Erlangen-Nuremberg, Erlangen, Germany, Erlangen, Germany, ²Royal Derby Hospital, Derby, UK, Derby, United Kingdom, ³Leon Medical Research, Lauderdale Lakes, USA, Lauderdale Lakes, FL, ⁴Statistics, GlaxoSmithKline, Stevenage, UK, Stevenage, United Kingdom, ⁵ImmunoInflammation, GlaxoSmithKline, Stevenage, UK, Stevenage, United Kingdom, ⁶Rheumatology, Antonius Ziekenhuis, Sneek, Netherlands, Sneek, Netherlands, ⁷Global Clinical Science & Delivery, ImmunoInflammation, GlaxoSmithKline, Stevenage, UK, Stevenage, United Kingdom, ⁸ImmunoInflammation, ImmunoInflammation, GlaxoSmithKline, Stevenage, UK, Stevenage, United Kingdom, ⁹ClinicMed Badurski i Wspólnicy Spółka Jawna, Białystok, Poland, Białystok, Poland
Background/Purpose: Previous data showed that neutralization of granulocyte/monocyte colony stimulating factor (GM-CSF) rapidly abolished pain in an experimental OA model suggesting GM-CSF may be a…
Abstract Number: 2896 • 2014 ACR/ARHP Annual Meeting
a Multi-Center Double-Blind, Randomized, Controlled Trial (db-RCT) to Evaluate the Effectiveness and Safety of Co-Administered Traumeel^® (Tr14) and Zeel^® (Ze14) Intra‑articular (IA) Injections Versus IA Placebo in Patients with Moderate-to-Severe Pain Associated with OA of the Knee
Carlos Lozada¹, Eve del Rio², Donald Reitberg², Robert Smith², Charles Kahn³ and Roland W. Moskowitz⁴, ¹Rheumatology, University of Miami Miller School of Medicine, Miami, FL, Miami, FL, ²Clinical Research, Rio Pharmaceutical Services, LLC, Bridgewater, NJ, ³South Florida Rheumatology, Hollywood, FL, ⁴Div of Rheum/Dept of Medicine, University Hospitals Case Medical Center, Cleveland, OH
Background/Purpose: Tr14 & Ze14 is a combination of dilute biological and mineral extracts administered IA for painful knee OA. In response to clinician impressions of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].